Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.50 |
| ▸ | PPARA | Q07869 | 8/20 | 0.50 |
| ▸ | PPARD | Q03181 | 5/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.48 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5991810 | 0.90 | PPARG (0.55) | PPARGPPARAPPARDFFAR1PTGES | |
| SCHEMBL6818192 | 0.82 | PPARG (0.47) | PPARGPPARAPPARDFFAR1LTA4H | |
| SCHEMBL6818759 | 0.80 | PPARG (0.48) | PPARGPPARAPPARDFFAR1LMNA | |
| SCHEMBL5992817 | 0.79 | PPARA (0.56) | PPARGPPARAPPARDFFAR1 | |
| SCHEMBL5992824 | 0.79 | PPARA (0.56) | PPARGPPARAPPARDFFAR1 | |
| SCHEMBL6821028 | 0.79 | PPARG (0.47) | PPARGPPARAPPARDFFAR1PTGES | |
| SCHEMBL5991298 | 0.79 | PPARA (0.67) | PPARGPPARAPPARD | |
| SCHEMBL5991287 | 0.79 | PPARA (0.67) | PPARGPPARAPPARD | |
| SCHEMBL3660194 | 0.78 | LTA4H (0.65) | PPARGPPARAPPARDFFAR1ALOX5 | |
| SCHEMBL7243191 | 0.77 | PPARG (0.52) | PPARGPPARAFFAR1PTGESALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060173204-A1 | New 3-aryl propionic acid derivatives and analogs | ANDERSSON KJELL | 2006-08-03 | — | — | US | disclosed |
| US-20040229949-A1 | New 3-aryl propionic acid derivatives and analogs | ANDERSSON KJELL (SE) | 2004-11-18 | — | — | US | disclosed |
| US-6630600-B1 | Intermediate for their manufacture, pharmaceutical preparations containing them and the use of the compounds in clinical conditions associated with insulin resistance. | ASTRAZENECA AB (SE) | 2003-10-07 | — | — | US | disclosed |
| EP-1084102-B1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| EP-1084102-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | AstraZeneca AB (SE) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999062871-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | ASTRAZENECA AB (SE) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229949-A1 | New 3-aryl propionic acid derivatives and analogs | GPR119, INSR, IRS1 | PPARG 22/4885PPARA 11/4885PPARD 8/4885 |
| US-20060173204-A1 | New 3-aryl propionic acid derivatives and analogs | GPR119, INSR, IRS1 | PPARG 22/4885PPARA 11/4885PPARD 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.